# COMT — Catechol-O-methyltransferase
URL: https://genohealth.app/genes/comt
Category: Cognitive & neurotransmitters
Chromosome: 22q11.21
Key variants: rs4680 (Val158Met)
Last reviewed: 2026-04-25

## Summary
COMT breaks down dopamine, norepinephrine, epinephrine and estrogens. The Val158Met variant (rs4680) influences stress resilience, working memory, pain sensitivity, and how you respond to caffeine, stimulants and methylated supplements.

## What it does
COMT clears catecholamines (dopamine, norepinephrine, epinephrine) from synapses, especially in the prefrontal cortex, and methylates 2- and 4-hydroxy estrogens for safe excretion. The Val (G) allele encodes a fast, thermostable enzyme; the Met (A) allele is ~3-4x slower, leading to higher baseline catecholamines and slower estrogen clearance.

## Why it matters
Met/Met (slow) carriers tend toward better focus and working memory at rest but worse performance under acute stress ("worrier" phenotype). Val/Val (fast) carriers tolerate stress better but have lower baseline prefrontal dopamine ("warrior" phenotype). The genotype affects optimal caffeine intake, response to stimulants like Adderall, tolerance of methyl-donor supplements, and estrogen-sensitive risks.

## Variants
- rs4680 (Val158Met (G→A)) — risk allele context-dependent; Met allele reduces enzyme thermostability and activity ~3-4x. (frequency: Met allele ≈50% in Europeans (Hardy-Weinberg balanced).)
- rs4633 — risk allele n/a; Synonymous variant in linkage with rs4680; often co-reported. (frequency: ≈50%)

## Genotypes
- **Val/Val (GG) — warrior** (~25%): Fast catecholamine clearance. Lower baseline prefrontal dopamine. Stress-resilient. Tolerates caffeine and stimulants well. → Use caffeine (2-4 cups/day), tyrosine, and protein-rich breakfast for focus. Methylfolate doses up to 1 mg usually well tolerated.
- **Val/Met (GA) — intermediate** (~50%): Mixed phenotype. → Standard guidance applies; titrate based on subjective response.
- **Met/Met (AA) — worrier** (~25%): Slow catecholamine clearance. Higher baseline dopamine. Stress-sensitive. Sensitive to caffeine, stimulants and methyl donors. → Cap caffeine at 1-2 cups, none after noon. Start methylfolate at 200 mcg or less. Use L-theanine, magnesium glycinate, and stress-management practices.

## Conditions
- **Anxiety disorders** — Modifies risk: Met/Met carriers report higher anxiety under acute stress but often perform better in low-stress focused work.
- **ADHD treatment response** — Modifies response: Val/Val carriers may respond better to amphetamine-class stimulants; Met/Met may experience more side effects.
- **Estrogen-driven conditions (fibroids, endometriosis)** — Modifies risk: Slow COMT impairs phase-II clearance of catechol estrogens; supporting methylation may help.
- **Chronic pain** — Increased sensitivity (Met/Met): Met/Met associated with higher pain sensitivity in TMD and fibromyalgia studies.

## Diet
Rationale: Met/Met carriers benefit from cofactors that support methylation without overwhelming an already-slow enzyme. Val/Val carriers benefit from tyrosine substrate to compensate for low baseline dopamine.
Prioritize: Protein-rich breakfast (Val/Val especially); Magnesium-rich foods (pumpkin seeds, dark chocolate, leafy greens); Cruciferous vegetables (estrogen support); Green tea (L-theanine)
Limit: Excessive caffeine if Met/Met; Quercetin in mega-doses (inhibits COMT); Heavy alcohol (depletes magnesium)

## Lifestyle
- Met/Met: prioritize daily stress-reduction (meditation, yoga, breathwork).
- Val/Val: high-stakes/high-stimulation environments may suit you; ensure adequate dopamine recovery.
- Both: 7-9 hours of sleep — sleep deprivation amplifies COMT-related variability.
- Resistance training raises baseline dopamine tone in Val/Val carriers.

## Supplements
- **Magnesium glycinate** — 200-400 mg/day, form: Glycinate or threonate. Cofactor for COMT; calming for Met/Met.
- **L-theanine** — 100-200 mg with caffeine, form: Suntheanine. Smooths the caffeine response, especially for Met/Met.
- **L-tyrosine (Val/Val only)** — 500-1500 mg morning, form: N-acetyl-tyrosine or free form. Avoid if Met/Met or on MAOIs.
- **Rhodiola rosea** — 200-400 mg morning, form: 3% rosavins, 1% salidroside. Adaptogen; supports stress resilience for both genotypes.
- **DIM (diindolylmethane)** — 100-200 mg/day, form: Bioavailable DIM. Supports estrogen phase-I metabolism upstream of COMT.

## Contraindications
- Met/Met + high-dose methylfolate (>1 mg) without titration — can trigger anxiety and irritability.
- Quercetin and EGCG in large doses inhibit COMT — caution if Met/Met.
- Stimulant medications (Adderall, modafinil) should be carefully titrated in Met/Met.

## FAQ
**Q: Why does coffee make me anxious?**
A: If you carry Met/Met COMT, your slower clearance of catecholamines plus caffeine's adrenergic effect can amplify anxiety. Try reducing dose, switching to L-theanine + low-dose caffeine, or moving to green tea.

**Q: Can slow COMT take methylfolate?**
A: Yes, but start low (200-400 mcg) and titrate over weeks. Many Met/Met carriers tolerate methylfolate fine — the issue is over-methylating too quickly. Pair with magnesium and avoid loading B-complexes.

**Q: What is the warrior vs worrier gene?**
A: The COMT Val158Met variant. Val/Val (warrior) handles acute stress well but has lower baseline focus dopamine. Met/Met (worrier) has better focus at rest but worse stress performance. Most people are Val/Met.

**Q: Does COMT affect estrogen?**
A: Yes. COMT methylates catechol estrogens (2-OH and 4-OH metabolites). Slow COMT may slow estrogen clearance; supporting methylation cofactors (magnesium, B-vitamins) and DIM can help.

**Q: Should Met/Met avoid caffeine entirely?**
A: Not necessarily. Many Met/Met carriers tolerate 1-2 cups before noon, especially with L-theanine. Listen to your jitter, sleep and afternoon-crash signals.

## Citations
- Egan et al., PNAS 2001 (PMID 11381111): Foundational paper linking COMT Val158Met to prefrontal cortex efficiency and working memory.
- Goldman et al., Pain 2005 (PMID 16213089): Met/Met associated with higher pain sensitivity and risk of TMD.
- Stein et al., Mol Psychiatry 2006 (PMID 16702977): Review of warrior vs worrier framework and clinical implications.

Disclaimer: Informational only — not medical advice.